or Try an Advanced Search...

    Hematological Malignancies Stocks List

    Symbol Grade Name % Change
    CERO F CERo Therapeutics Holdings, Inc. -5.54
    ALRN F Aileron Therapeutics, Inc. 2.90
    CNTA D Centessa Pharmaceuticals plc -2.17
    SNDX D Syndax Pharmaceuticals, Inc. -2.81
    ADAP D Adaptimmune Therapeutics plc -2.86
    ABBV C AbbVie Inc. -1.28
    MRKR C Marker Therapeutics, Inc. -0.95
    PSTX B Poseida Therapeutics, Inc. -2.65
    TGTX B TG Therapeutics, Inc. 2.62
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Other
    Related Stock Lists: Cancer Solid Tumors Biopharmaceutical Immunotherapy Lymphoma Medicine Cancer Immunotherapy Cancer Treatment Clinical Medicine Immune System Treatment Of Cancer Tumor Virotherapy Adoptive Cell Transfer Cell Therapy Lung Cancer Non Small Cell Lung Cancer Oncogenes Ovarian Cancer Peptides

    Related ETFs - A few ETFs which own one or more of the above listed Hematological Malignancies stocks.

    Symbol Grade Name Weight
    MEDI D Harbor Health Care ETF 10.38
    BOTZ C Global X Robotics & Artificial Intelligence Thematic ETF 10.01
    HDLB C ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B due September 30, 2044 9.8
    GRID C First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund 8.31
    FDL B First Trust Morningstar ETF 8.12
    View all Hematological Malignancies ETFs...
    Compare ETFs
    Compare HDLB to FDL Compare MEDI to BOTZ Compare MEDI to HDLB

        Hematological Malignancies Stocks Recent News

        Date Stock Title
        Jul 3 ABBV AbbVie Q2 IPR&D expenses to lower EPS by $0.52
        Jul 3 ADAP Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
        Jul 3 ABBV Company News for Jul 3, 2024
        Jul 3 ADAP 5 FDA decisions to watch in the third quarter
        Jul 3 ABBV AbbVie: A Hold Again (Rating Downgrade)
        Jul 2 ADAP Fireside Chat with Adrian Rawcliffe, Chief Executive Officer of Adaptimmune
        Jul 2 ABBV With 72% ownership, AbbVie Inc. (NYSE:ABBV) boasts of strong institutional backing
        Jul 2 ABBV AbbVie to Host Second-Quarter 2024 Earnings Conference Call
        Jul 1 PSTX Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
        Jul 1 ABBV 2 High-Yielding Healthcare Stocks to Buy With $1,000 in July
        Jul 1 ABBV AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
        Jul 1 ABBV AbbVie names Robert A. Michael to CEO role
        Jul 1 ABBV Robert A. Michael Assumes Role as AbbVie Chief Executive Officer
        Jul 1 ALRN Aileron Therapeutics to be Included in the Russell Microcap® Index
        Jul 1 ABBV 3 Magnificent Stocks Retirees Can Buy and Hold Forever
        Jul 1 ABBV 10 clinical trials to watch in the second half of 2024
        Jun 29 ABBV How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth?
        Jun 28 ABBV How Medicare drug price negotiations could hit pharma stocks
        Jun 28 ABBV Coherus offloads Humira biosimilar Yusimry for $40m
        Jun 28 ABBV AbbVie Insiders Sold US$56m Of Shares Suggesting Hesitancy
        Related Industries: Biotechnology Drug Manufacturers - Major Other
        Related Stock Lists: Cancer Solid Tumors Biopharmaceutical Immunotherapy Lymphoma Medicine Cancer Immunotherapy Cancer Treatment Clinical Medicine Immune System Treatment Of Cancer Tumor Virotherapy Adoptive Cell Transfer Cell Therapy Lung Cancer Non Small Cell Lung Cancer Oncogenes Ovarian Cancer Peptides
        Hematological Malignancies

        Hematological malignancies are cancers of the blood, bone marrow, and lymphatic system. These cancers can affect the production and function of blood cells, leading to a variety of symptoms and complications. Common types of hematological malignancies include leukemia, lymphoma, and multiple myeloma. Treatment for these cancers may include chemotherapy, radiation therapy, and/or stem cell transplantation.

        Browse All Tags